Filtered By:
Condition: Headache
Education: Grants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Extreme Heat Is Endangering America ’ s Workers —And Its Economy
This project was supported by the Pulitzer Center
7 A.M.: COPELAND FARMS—ROCHELLE, GA
Just after dawn on a recent July day in Rochelle, Ga., Silvia Moreno Ayala steps into a pair of sturdy work pants, slips on a long-sleeved shirt, and slathers her face and hands with sunscreen. She drapes a flowered scarf over her wide-brimmed hat to protect her neck and back from the punishing rays of the sun. There isn’t much she can do about the humidity, however. Morning is supposed to be the coolest part of the day, but sweat is already pooling in her rubber boots.
[time-brightcove not-tgx=”true”]
...
Source: TIME: Health - August 3, 2023 Category: Consumer Health News Authors: Aryn Baker / Georgia Tags: Uncategorized climate change Climate Is Everything feature healthscienceclimate Source Type: news
Will unpredictable side effects dim the promise of new Alzheimer ’s drugs?
A sea change is underway in the treatment of Alzheimer’s disease, where for the first time a drug that targets the disease’s pathology and clearly slows cognitive decline has hit the U.S. market. A related therapy will likely be approved in the coming months. As many neurologists, patients, and brain scientists celebrate, they’re also nervously eyeing complications from treatment: brain swelling and bleeding, which in clinical trials affected up to about one-third of patients and ranged from asymptomatic to fatal.
The side effect—amyloid-related imaging abnormalities, or ARIA—remains mysterious. “We don’...
Source: Science of Aging Knowledge Environment - August 2, 2023 Category: Geriatrics Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Concussions and kids: Project co-led by UCLA gets $10 million grant from NIH
A research project co-led by theUCLA Steve Tisch BrainSPORT Programaimed at improving the assessment and treatment of concussions in school-aged children has been awarded $10 million by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health.The grant to the Four Corners Youth Consortium, agroup of academic medical centers studying pediatric concussions, will supportConcussion Assessment, Research and Education for Kids, or CARE4Kids, a multisite study that will enroll more than 1,300 children and teens nationwide, including an estimated 240 in Southern California.CARE4Kids re...
Source: UCLA Newsroom: Health Sciences - October 7, 2021 Category: Universities & Medical Training Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Leading migraine researcher supported by the NIH wins The Brain Prize 2021
(NIH/National Institute of Neurological Disorders and Stroke) The Brain Prize has been awarded to Michael A. Moskowitz, M.D., a professor of neurology at Harvard Medical School at the Massachusetts General Hospital, Charlestown, who also is supported by an NIH grant.
Source: EurekAlert! - Medicine and Health - March 5, 2021 Category: International Medicine & Public Health Source Type: news
Intravenous Thrombolysis in Posterior Circulation Stroke
Conclusions: Up to date, no data about PCIS and IVT are available from RTCs. Based on limited results from retrospective clinical studies and case series, IVT is safer for use in PCIS than in ACIS. Patients with brainstem ischemia, vertebral artery occlusion, and absence of basilar or posterior cerebral artery occlusion could be considered for treatment with IVT even in borderline cases. Time to IVT in PCIS seems to be a less crucial factor than in ACIS. IVT for PCIS may be beneficial even after 4.5 h from symptom onset.
Introduction
History of Intravenous Thrombolysis—The Most Relevant Studies
Intravenous...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research
Harnessing the Four Elements for Mental Health
DiscussionAs detailed above, the “elements” in both a classical and a contemporary sense have effects on our mental health and are potentially modifiable aspects that can be harnessed as therapeutic interventions. The most robust interventional evidence currently available shows tentative support for several use of the elements via horticultural and nature-exposure therapy, green exercise/physical activity, sauna and heat therapy, balneotherapy, and breathing exercises. It should be noted that, in many cases, these interventions were not studied in definitive diagnosed psychiatric disorders and thus it is pre...
Source: Frontiers in Psychiatry - April 23, 2019 Category: Psychiatry Source Type: research
The Predictive Capacity of the Buffalo Concussion Treadmill Test After Sport-Related Concussion in Adolescents
Conclusion
This study found that the ΔHR (HRt minus resting HR) correlated with duration of clinical recovery in participants who were prescribed relative rest or a placebo-stretching program but not for participants prescribed sub-threshold aerobic exercise. A ΔHR of ≤50 bpm on the BCTT was 73% sensitive and 78% specific for predicting delayed recovery in concussed adolescents prescribed the current standard of care (i.e., cognitive and physical rest). This has implications for planning team and school activities in adolescents who sustain SRC.
Ethics Statement
This study was carried out in acco...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research
A Chinese Family With Adult-Onset Leigh-Like Syndrome Caused by the Heteroplasmic m.10191T > C Mutation in the Mitochondrial MTND3 Gene
Conclusion
The m.10191T>C mutation in the mtDNA of the complex I (CI) subunit of MTND3 results in the substitution of a highly conserved amino acid (p.Ser45Pro) within the ND3 protein, leading to CI dysfunction through impaired enzyme catalysis rather than impaired stability or assembly, causing a broad clinical spectrum of disorders (26). Patients with the m.10191T>C mutation are rare. In the present study, we report on a family of patients with the extremely rare adult-onset Leigh-like syndrome with the m.10191T>C mutation.
Including the two patients from our reported family, the m.10191T...
Source: Frontiers in Neurology - April 17, 2019 Category: Neurology Source Type: research
Isolation of Antimicrobial Compounds From Cnestis ferruginea Vahl ex. DC (Connaraceae) Leaves Through Bioassay-Guided Fractionation
Conclusion
In conclusion, aqueous extracts of C. ferruginea leaves showed antimicrobial activity due to the presence of hydroquinone and caffeic acid methyl ester. This supports its traditional use for infections and confirmed that the active molecules are water-soluble.
Author Contributions
KK, SP, LVP, and WL conceived and designed the experiments. SP, KK, M-RY, and J-GL performed the experiments. SP, LVP, WL, M-RY, J-GL, and Z-HJ analyzed the data. WL and Z-HJ contributed reagents, materials, and analysis tools. KK, SP, WL, M-RY, Z-HJ, and LVP contributed to the writing of the manuscript. All authors contributed to m...
Source: Frontiers in Microbiology - April 10, 2019 Category: Microbiology Source Type: research
Pre-injury Comorbidities Are Associated With Functional Impairment and Post-concussive Symptoms at 3- and 6-Months After Mild Traumatic Brain Injury: A TRACK-TBI Study
Conclusions: Pre-injury psychiatric and pre-injury headache/migraine symptoms are risk factors for worse functional and post-concussive outcomes at 3- and 6-months post-mTBI. mTBI patients presenting to acute care should be evaluated for psychiatric and headache/migraine history, with lower thresholds for providing TBI education/resources, surveillance, and follow-up/referrals.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01565551.
Introduction
Traumatic brain injury (TBI) remains a significant cause of morbidity and mortality worldwide. In 2013 ~2.8 million TBI cases were recorded an...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research
Seurat Therapeutics gets $500K for its migraine-fighting nasal spray
A Chicago-based medical startup that wants to stop migraines using a nasal spray received more funding this week to continue its research.
Seurat Therapeutics, a biotech startup founded within the University of Chicago, received a $500,000 grant from the National Institute of Neurological Disorders and Stroke.
The funding will help the startup continue testing its product, a nasal spray that aims to stop the cause of migraines. The funding comes after the company raised $750,000 in seed funding…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 19, 2018 Category: Pharmaceuticals Authors: Tatiana Walk-Morris Source Type: news
